Objective: We aimed to evaluate SIGLEC1 (CD169) as a biomarker in Multiple Sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the specificity of SIGLEC1+ myeloid cells for demyelinating diseases Methods: We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1+ myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. Results: We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. SIGLEC1+ myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. Conclusion: In our cohort, SIGLEC1 expression on monocytes was - apart from those patients receiving interferon treatment - not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. The presence of SIGLEC1+ myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.

中文翻译：

---

SIGLEC1（CD169）：MS患者脑部而非血液中活动性神经炎症的标志物

目的：我们旨在评估SIGLEC1（CD169）作为多发性硬化症（MS）和视神经脊髓炎谱系疾病（NMOSD）的生物标志物，并评估SIGLEC1 +髓样细胞对脱髓鞘疾病的特异性方法：我们进行了基于流式细胞术的SIGLEC1测量86名MS患者，41名NMOSD患者和31名健康对照的单核细胞表达。此外，我们在组织学上评估了急性和慢性MS脑损伤以及其他神经系统疾病中SIGLEC1 +髓样细胞的存在。结果：我们发现16/86（18.6％）MS患者和4/41（9.8％）NMOSD患者中SIGLEC1表达升高。几乎所有具有高SIGLEC1水平的MS患者都接受外源性干扰素β的免疫调节治疗，只有一小部分未经干扰素治疗的MS患者的SIGLEC1表达增加。SIGLEC1 +髓样细胞大量存在于活动性MS病变以及一系列中枢神经系统的急性感染和恶性疾病中，但不存在于慢性MS病变中。结论：在我们的队列中，除接受干扰素治疗的患者外，单核细胞上的SIGLEC1表达未在MS和NMOSD患者中显着增加，也未与更严重的疾病相关。脑损伤中SIGLEC1 +髓样细胞的存在可用于研究炎性CNS损伤中的活性。SIGLEC1 +髓样细胞大量存在于活动性MS病变以及一系列中枢神经系统的急性感染和恶性疾病中，但不存在于慢性MS病变中。结论：在我们的队列中，除接受干扰素治疗的患者外，单核细胞上的SIGLEC1表达未在MS和NMOSD患者中显着增加，也未与更严重的疾病相关。脑损伤中SIGLEC1 +髓样细胞的存在可用于研究炎性CNS损伤中的活性。SIGLEC1 +髓样细胞大量存在于活动性MS病变以及一系列中枢神经系统的急性感染和恶性疾病中，但不存在于慢性MS病变中。结论：在我们的队列中，除接受干扰素治疗的患者外，单核细胞上的SIGLEC1表达未在MS和NMOSD患者中显着增加，也未与更严重的疾病相关。脑损伤中SIGLEC1 +髓样细胞的存在可用于研究炎性CNS损伤中的活性。水平也与更严重的疾病无关。脑损伤中SIGLEC1 +髓样细胞的存在可用于研究炎性CNS损伤中的活性。水平也与更严重的疾病无关。脑损伤中SIGLEC1 +髓样细胞的存在可用于研究炎性CNS损伤中的活性。